Skip to content

Accuracy and Reliability of GSA for Remnant Liver Function

Accuracy and Reliability of GSA for Remnant Liver Function in Scheduled Hepatectomized Patients

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT02013895
Acronym
GSA
Enrollment
Unknown
Registered
2013-12-17
Start date
Unknown
Completion date
Unknown
Last updated
2013-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Both Benign and Malignant Liver Mass

Keywords

liver, surgery, liver function, GSA, ICG

Brief summary

Preoperative evaluation of future remnant liver function is critical for patients undergoing hepatic surgery. Overestimation of the remnant liver function can lead to life-threatening postoperative hepatic failure, and its underestimation can lead to a lost opportunity for potentially curative surgery. Conventionally, post-hepatectomy remnant liver function has been estimated preoperatively using computed tomography (CT) volumetry. CT can provide precise anatomical information, and the remnant liver volume, measured by CT volumetry, has been reported to be an effective predictor of hepatic dysfunction after hepatectomy. However, the indirect estimation of liver function by CT volumetry is reliable only when the function is assumed to be homogenous over the whole liver.

Detailed description

99mTc-galactosyl human serum albumin (99mTc-GSA) single-photon emission CT (SPECT) was developed to facilitate investigations of regional hepatic function. A disadvantage of conventional 99mTc-GSA SPECT was poor anatomical resolution, and this newly developed SPECT has a tremendously improved anatomical resolution owing to the fusion of CT and 99mTc-GSA SPECT. Recent reports have indicated that accurate regional function, based on precise anatomical information, could be evaluated using this technique.

Interventions

DEVICE99mTc-GSA

Sponsors

Kochi University
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL

Inclusion criteria

* All eligible patients were those surgically treated for hepato-biliary diseases.

Exclusion criteria

* Patient

Countries

Japan

Contacts

Primary ContactTakehiro Okabayashi, MD PhD
takehiro_okabayashi@khsc.or.jp+81 88-837-3000
Backup ContactYasuo Shima
+81 88-837-3000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026